Brief: Precigen Receives FDA Platform Technology Designation For Adenoverse Platform
21/09/2026 13:10
BRIEF-Precigen Receives FDA Platform Technology Designation For Adenoverse Platform Sept 21 (Reuters) - Precigen, Inc. PGEN.O:
PRECIGEN RECEIVES FDA PLATFORM TECHNOLOGY DESIGNATION FOR ADENOVERSE PLATFORM
Source text: ID:nPn8Wr0vPa
Further company coverage: PGEN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Precigen
See all newsBrief: Precigen Receives FDA Platform Technology Designation For Adenoverse Platform
Precigen, Inc. reports results for the quarter ended June 30 - Earnings Summary
Precigen posts quarterly profit as PAPZIMEOS sales surge
Precigen Inc expected to post a loss of 1 cent a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Advanced Energy, Bel Fuse, Cerebras